Free MRSO GBCA Safety & NSF Screening Questions and Answers — Questions and Answers
Question 1: Which patient condition represents the most significant risk factor for developing Nephrogenic Systemic Fibrosis (NSF)?
- Chronic liver disease or cirrhosis
- Acute kidney injury or severe chronic kidney disease (Correct answer)
- A history of severe allergic reactions to iodinated contrast
- Diabetes mellitus with normal renal function
Correct answer: Acute kidney injury or severe chronic kidney disease
NSF is a rare but serious condition strongly associated with patients who have impaired renal function. Specifically, those with acute kidney injury (AKI) or severe chronic kidney disease (e.g., GFR < 30 mL/min/1.73m²) are at the highest risk because their kidneys cannot effectively clear the GBCA from the body.
Question 2: According to the ACR Manual on Contrast Media, for which group of patients is a recent eGFR assessment most critical before administering a GBCA?
- All patients over the age of 50
- Patients with a history of hypertension, diabetes, or age > 60 years (Correct answer)
- All pregnant patients
- Any patient receiving a GBCA for the very first time
Correct answer: Patients with a history of hypertension, diabetes, or age > 60 years
The ACR recommends screening for renal dysfunction in patients with known risk factors. These include age over 60, a history of hypertension requiring medical therapy, or a history of diabetes, as these conditions increase the likelihood of underlying chronic kidney disease.
Question 3: GBCAs are classified into groups based on risk. Which group has been associated with the vast majority of documented NSF cases?
- Group I (Linear agents) (Correct answer)
- Group II (Macrocyclic agents)
- Group III (Newer agents with limited data)
- All groups carry an identical and negligible risk
Correct answer: Group I (Linear agents)
Group I agents, which have a linear molecular structure, are less stable and more likely to release free gadolinium ions in the body. These agents have been associated with the greatest number of unconfounded, documented cases of NSF, leading to restricted use in many countries.
Question 4: What is the current FDA understanding of gadolinium retention in patients with normal renal function?
- Gadolinium is completely cleared from the body within 24 hours
- Retention is a theoretical risk that has not been proven in humans
- Trace amounts of gadolinium can be retained in tissues like the brain and bone (Correct answer)
- Retention only occurs in patients who go on to develop NSF
Correct answer: Trace amounts of gadolinium can be retained in tissues like the brain and bone
Studies have demonstrated that even in patients with normal kidneys, trace amounts of gadolinium can be retained long-term in various body tissues, most notably the brain (dentate nucleus, globus pallidus) and bone. The long-term clinical significance of this retention is still being investigated.
Question 5: What is the general recommendation regarding the use of GBCAs in pregnant patients?
- GBCAs are strictly contraindicated in all trimesters of pregnancy
- Use only if the diagnostic information is essential and cannot be obtained by other means (Correct answer)
- It is considered completely safe to use after the first trimester
- The standard adult dose can be used without any special consideration
Correct answer: Use only if the diagnostic information is essential and cannot be obtained by other means
GBCAs are known to cross the placenta and enter the fetal circulation, where the gadolinium is cleared by the fetal kidneys into the amniotic fluid. Due to unknown effects on the fetus, their use is reserved for cases where the diagnostic benefit clearly outweighs the potential risk and the information cannot be obtained otherwise.
Question 6: A 68-year-old patient with a history of diabetes is scheduled for a contrast-enhanced MRI. Their chart shows a normal eGFR from 10 months ago. What is the most appropriate action?
- Proceed with the scan, as a previous normal test is on file
- Require a new creatinine/eGFR measurement before administering contrast (Correct answer)
- Administer a half-dose of a Group II GBCA to be safe
- Cancel the scan and recommend a non-contrast study instead
Correct answer: Require a new creatinine/eGFR measurement before administering contrast
For patients with risk factors for renal disease, institutional policies, guided by ACR recommendations, typically require a recent renal function assessment (e.g., within 6 weeks). A 10-month-old result is not considered current enough to ensure patient safety, as kidney function can change over time.
Free MRSO GBCA Safety & NSF Screening Questions and Answers
Which patient condition represents the most significant risk factor for developing Nephrogenic Systemic Fibrosis (NSF)?